Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy

To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy...

Full description

Saved in:
Bibliographic Details
Published in:Acta neuropathologica communications 2014-10, Vol.2 (1), p.154-154, Article 154
Main Authors: Aouizerate, Jessie, De Antonio, Marie, Bassez, Guillaume, Gherardi, Romain K, Berenbaum, Francis, Guillevin, Loïc, Berezne, Alice, Valeyre, Dominique, Maisonobe, Thierry, Dubourg, Odile, Cosnes, Anne, Benveniste, Olivier, Authier, François Jérôme
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antibodies
Antigens
Biomarkers
Comparative analysis
Dermatomyositis - metabolism
Dermatomyositis - pathology
Female
Genetic aspects
HLA Antigens - metabolism
HLA-DR Antigens - metabolism
Humans
Male
Middle Aged
Muscle, Skeletal - metabolism
Muscle, Skeletal - pathology
Myositis - metabolism
Myositis - pathology
Viral antibodies
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy (n = 10) were first reviewed. ASAb included anti-Jo1 (26/33), anti-PL12 (4/33), anti-PL7 (2/33), and anti-EJ (1/33). Immunohistochemistry was performed for MHC-I/HLA-ABC, MHC-II/HLA-DR, membrane attack complex (C5b-9), neural cell adhesion molecule (NCAM)/CD56 expression, and inflammatory cell subsets. Twenty-four ASM and 12 DM patients from another center were added for HLA-DR evaluation. Ubiquitous myofiber HLA-ABC expression was equally observed in ASM and DM (93.9% vs 100%, NS). In contrast, myofiber HLA-DR expression was found in 27/33 (81.8%) ASM (anti-Jo1: 23/26, 88.5%; others: 5/7, 71.4%) vs 4/17 (23.5%) DM patients (p 
ISSN:2051-5960
2051-5960
DOI:10.1186/s40478-014-0154-2